Prognosis is a horizon scanning service that monitors emerging health technologies as they go through clinical trial development and the regulatory approval process.
I am looking for…
View a sampling of our Prognosis reports.
Plenity (formerly Gelesis100 and GSP3) is an oral, non-systemic, superabsorbent hydrogel intended as an aid in weight management in overweight and obese adults with a body mass index (BMI) of 25-40 kg/m2, when used in conjunction with diet and exercise.
Erdafitinib is an oral kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible fibrobrast growth factor receptor 3 (FGFR3) or FGFR2 genetic alterations, and has progressed during or following at least 1 line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
Golodirsen (SRP-4053) is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer subclass intended to skip exon 53 of the DMD gene and enable the synthesis of a truncated but functional dystrophin protein. Only patients carrying a mutation in exon 53 will be amenable to this treatment.
NeuroAD is noninvasive system that combines repetitive transcranial magnetic stimulation with cognitive training to treat mild-to-moderate Alzheimer disease. Transcranial magnetic stimulation (TMS) is a neurostimulation and neuromodulation method that uses electromagnetic induction of electric fields in the brain. TMS works by passing a current through a wire coil placed on the scalp; the transient current produces a magnetic field, which induces electric current in the underlying brain. It is proposed that this stimulation induces long-term potentiation, which is associated with learning and memory processes, and makes these areas of the brain more receptive to cognitive training.
The SSO2 Therapy system is intended for use in acute anterior myocardial infarction patients following percutaneous coronary intervention (PCI) performed within 6 hours of symptom onset. The system delivers supersaturated oxygen mixed with the patient’s own blood to the left anterior descending coronary artery, with the goal of further reducing infarct size.